Browse Technologies

Displaying 1 - 10 of 33


Small Molecule Theraputics That Target the Muscarinic Acetylcholine Receptor 1 For The Treatment of Alzheimer's Disease

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Small Molecule mGlu5 NAMs For The Treatment of Depressive Disorders or Parkinson's Disease

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


Novel Therapeutic Strategy for Remyelination and Repair of Nerve Injury

Demyelinating injury is notoriously difficult due to an absence of treatments that stimulate the repair and reconstruction of the myelin sheath that insulates the nerves. Dr. Subramaniam Sriram has discoverd that remyelination in the central nervous system can be stimulated through direct or indirect activation of the Toll-like receptor 3 (TLR3) signaling pathway or interleukin 33 (IL-33).


Licensing Contact

Mike Villalobos
mike.villalobos@vanderbilt.edu
615.322.6751

Inventors

Subramaniam Sriram
Therapeutics
Neuroscience/Neurology

Small Molecule mGlu3 NAMs as Therapeutics for CNS Disorders

The Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) has a mission to promote the translation of advances in basic science towards novel therapeutics. They have recruited faculty and staff with experience at over 10 different pharmaceutical companies to ensure a diverse set of approaches, techniques and philosophies to advancing compounds. Together they aim to de-risk drug discovery programs.


mGlu3 NAMs as Therapeutics for Chemoresistant Tumors

Targeting metabotropic glutamate receptor 3 (mGlu3) has been linked as a potential therapeutic to many neurological disorders and well as oncology through the use of dual specific mGlu2/3 Antagonists (LY341495, RO4491533, MGS0039, RO4988546).


Rabbit Anti-human Large Neutral Amino Acid Transporter Antibody

This research targets LAT-1.


Licensing Contact

Karen Rufus
karen.rufus@vanderbilt.edu
615.322.4295

Inventors

Roy Zent
Research Tools
Antibody

Rabbit Anti-Fibroblast Specific Protein 1 Polyclonal Antibody

This research targets FSP1.


Licensing Contact

Karen Rufus
karen.rufus@vanderbilt.edu
615.322.4295

Inventors

Eric Neilson
Research Tools
Antibody